Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease

Yuan Hung Yeh, Po Hui Wang, Long Yau Lin, Yi Torng Tee, Ming Chih Chou, Shun Fa Yang, Hsiu Ting Tsai

Research output: Contribution to journalArticle

4 Citations (Scopus)


Background: To determine expression levels of urokinase-type plasminogen activator (uPA), soluble urokinase-type plasminogen activator receptor (suPAR), plasminogen activator inhibitor-1 (PAI-1) in plasma and to identify gene polymorphisms specific to patients with pelvic inflammatory disease (PID) and healthy controls. Methods: Enzyme-linked immunosorbent assay and polymerase chain reaction-restriction fragment length polymorphism were used to measure plasma levels and polymorphisms in uPA, suPAR, and PAI-1 among seventy healthy controls and 64 PID patients before and after they received routine treatment protocols. Results: The levels of plasma uPA (ng/ml) and soluble suPAR (pg/ml) were significantly increased in PID patients (uPA: 0.57 ± 0.03; suPAR: 1372.04 ± 68.20) when compared to that in normal controls (uPA: 0.55 ± 0.06, p = 0.002; suPAR: 1192.46 ± 51.98, p = 0.04); moreover, suPAR decreased significantly after treatment when compared to levels noted in the same patients (1220.06 ± 58.14; p = 0.003) after they received treatment. The increased expression of suPAR was significantly correlated with WBC counts (r = 0.382, p = 0.002, n = 64) in blood as well as the plasma levels of CRP (r = 0.441, p.

Original languageEnglish
Pages (from-to)138-144
Number of pages7
JournalClinica Chimica Acta
Publication statusPublished - Jan 16 2013
Externally publishedYes



  • Pelvic inflammatory disease
  • Polymorphism
  • Soluble urokinase-type plasminogen activator receptor
  • Urokinase-type plasminogen activator

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this